Inclusion Criteria:  Age equal to or greater than 18 years. Patients with positive antigen test or RT-PCR for SARS-CoV-2. Patients with less than 7 days from symptoms onset. Patients with indication for outpatient management. Patients with mild disease according to the official guide "Pneumonia Diagnosis and Treatment Scheme for Novel Coronavirus Infection (Trial Version 8)": Subjects with mild symptoms, with or without radiological signs of pneumonia, with oxygen saturation>90% . - Able to provided consent to participate.  Exclusion Criteria:  Patients who at the time of admission require hospitalization and / or supplemental oxygen. Known history of allergy to ivermectin. Known medical history of liver disease. Belong to another clinical trial evaluating the efficacy of an investigational drug against COVID-19.  The following comorbidities:  Immunosuppression or HIV. Acute or chronic kidney failure. Current neoplasia. Currently use of warfarin, erdafitinib, or quinidine. Have received vaccination for SARS-CoV-2. Ivermectin consumption prior to inclusion in the research protocol. The patient does not accept the conditions of home care and monitoring. The patient desists from participating in the study. Women in pregnancy or breastfeeding.